Skip to main content

Advertisement

SpringerLink
Log in

Telaprevir-induced, but not pegylated interferon-associated, retinopathy as a noteworthy adverse effect during triple antiviral therapy in patients with chronic hepatitis C

  • Rapid Communication
  • Published:
Journal of Gastroenterology Aims and scope Submit manuscript

Abstract

Background

The significance of retinopathy during triple therapy with telaprevir is uncertain.

Methods

Ophthalmologic examination was done prospectively before and every month during the therapy in 95 CHC patients.

Results

Retinopathy was found in 46 (48.4 %), and the specialists recommended discontinuation of the therapy in 9 (9.5 %). Such lesions may develop as adverse effects by telaprevir, since the lesions disappeared following discontinuation of telaprevir in a 65-year-old man, in whom both pegylated-interferon (Peg-IFN) and ribavirin were continued, and reappeared when he took telaprevir again by his decision. Multivariate analysis revealed that interleukin 28B single-nucleotide polymorphism (IL28B SNP) and anemia development during the therapy were independent factors associating retinopathy.

Conclusion

Ophthalmologic examinations should be done carefully during triple therapy, since the incidence was higher than that in previous Peg-IFN therapy, and lesions may develop as adverse effects by telaprevir, but not by Peg-IFN, especially in those showing preferable IL28B SNPs allele and/or anemia during the therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Kumada H, Toyota J, Okanoue T, et al. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol. 2012;56:78–84.

    Article  CAS  PubMed  Google Scholar 

  2. Hayashi N, Okanoue T, Tsubouchi H, et al. Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C. J Viral Hepat. 2012;19:e134–42.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  3. Chayama K, Hayes CN, Ohishi W, et al. Treatment of chronic hepatitis C virus infection in Japan: update on therapy and guidelines. J Gastroenterol. 2013;48:1–12.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. Vujosevic S, Tempesta D, Noventa F, et al. Pegylated interferon-associated retinopathy is frequent in hepatitis C virus patients with hypertension and justifies ophthalmologic screening. Hepatology. 2012;56:455–63.

    Article  CAS  PubMed  Google Scholar 

  5. Okuse C, Yotsuyanagi H, Nagase Y, et al. Risk factors for retinopathy associated with interferon alpha-2b and ribavirin combination therapy in patients with chronic hepatitis C. World J Gastroenterol. 2006;12:3756–9.

    CAS  PubMed  Google Scholar 

  6. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C. Nature Genet. 2009;41:1105–9.

    Article  CAS  PubMed  Google Scholar 

  7. Ochi H, Maekawa T, Abe H, et al. ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy: a genome-wide study of Japanese HCV virus patients. Gastroenterology. 2010;139:1190–7.

    Article  CAS  PubMed  Google Scholar 

  8. Fujiwara K, Mochida S, Matsuo S, et al. Randomized control trial of interferon-β injections at 12-h intervals as a therapy for chronic hepatitis C. Hepatol Res. 1998;12:240–51.

    Article  Google Scholar 

  9. Fujimori K, Mochida S, Matsui A, et al. Possible mechanisms of elevation of serum transaminase levels during interferon-β therapy in chronic hepatitis C patients. J Gastroenterol. 2002;37:40–6.

    Article  CAS  PubMed  Google Scholar 

  10. Mawatari H, Yoneda M, Kirikoshi H, et al. Thrombocytopenia is more severe in patients with chronic hepatitis C than in patients with nonalcoholic fatty liver disease. J Gastroenterol. 2012;47:606–7.

    Article  PubMed  Google Scholar 

  11. Kobayashi T, Hige S, Terashita K, et al. Anemia and thrombocytosis induced by ribavirin monotherapy in patients with chronic hepatitis C. J Gastroenterol. 2012;47:1228–37.

    Article  CAS  PubMed  Google Scholar 

  12. Lotrich FE, Loftis JM, Ferrell RE, et al. IL28B polymorphisms is associated with both side effects and clearance of hepatitis C during interferon-alpha therapy. J Interf Cytokine Res. 2011;31:331–6.

    Article  CAS  Google Scholar 

  13. Sommereyns C, Paul S, Staeheli P, et al. IFN-lambda is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog. 2008;4:e1000017.

    Article  PubMed Central  PubMed  Google Scholar 

  14. Nagaoka T, Sato E, Takahashi A, et al. Retinal circulatory change associated with interferon-induced retinopathy in patients with hepatitis C. Invest Ophthalmol Vis Sci. 2007;48:368–75.

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

Satoshi Mochida received research grants from Bristol-Myers Squibb Company, Janssen Pharmaceutical K.K., Chugai Pharmaceutical Co. Ltd., and lecture fees from MSD, Toray Industries, Bristol-Myers Squibb Company, and Mitsubishi Tanabe Pharma.

Author information

Authors and Affiliations

  1. Department of Gastroenterology and Hepatology, Faculty of Medicine, Saitama Medical University, 38 Morohongo, Moroyama-Machi, Iruma-Gun, Saitama, 350-0495, Japan

    Kayoko Sugawara, Mie Inao, Nobuaki Nakayama & Satoshi Mochida

Authors
  1. Kayoko Sugawara
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mie Inao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nobuaki Nakayama
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Satoshi Mochida
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Satoshi Mochida.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sugawara, K., Inao, M., Nakayama, N. et al. Telaprevir-induced, but not pegylated interferon-associated, retinopathy as a noteworthy adverse effect during triple antiviral therapy in patients with chronic hepatitis C. J Gastroenterol 49, 363–368 (2014). https://doi.org/10.1007/s00535-013-0889-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00535-013-0889-8

Keywords

Search

Navigation